Silver Book Fact

Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.

Harris S, Watts N, Genant H, McKeever C, et al. Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: A randomized controlled trial. JAMA. 1999; 282(14): 1344-52. http://jama.ama-assn.org/cgi/content/abstract/282/14/1344

Reference

Title
Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women with Postmenopausal Osteoporosis: A randomized controlled trial
Publication
JAMA
Publication Date
1999
Authors
Harris S, Watts N, Genant H, McKeever C, et al.
Volume & Issue
Volume 282, Issue 14
Pages
1344-52
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • Randomized controlled trials give evidence that pharmacologic therapy can reduce risk of fractures by 40 to 50%.  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
  • An Alzheimer’s disease treatment breakthrough that slowed its progression and began to show its effects in 2015, would reduce the costs of care for all people with the disease by…  
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.